Surface Oncology, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization expense
Stock-based compensation expense
Non-cash interest expense related to note payable
Net amortization of premiums and discounts on marketable securities
Loss on disposal of property and equipment
Non-cash operating lease cost
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Unbilled receivable
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred rent
Operating lease liability
Deferred revenue - related party
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of marketable securities
Proceeds from sales or maturities of marketable securities
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Payments of initial public offering costs
Proceeds from initial public offering of common stock, net of commissions and underwriting discounts
Proceeds from issuance of common stock to a related party
Proceeds from issuance of convertible note payable, net of issuance costs
Payments of debt issuance costs
Proceeds for issuance of common stock, net
Proceeds from employee stock purchases
Proceeds from exercise of stock options
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of period
Cash and cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Supplemental disclosure of non-cash investing and financing activities:
Accretion of redeemable convertible preferred stock to redemption value
Purchases of property and equipment included in accounts payable and accrued expenses
Additional right-of-use asset and related lease liability
Conversion of note payable into shares of common stock

Comments